EA201590202A1 - Опиоидные препараты - Google Patents

Опиоидные препараты

Info

Publication number
EA201590202A1
EA201590202A1 EA201590202A EA201590202A EA201590202A1 EA 201590202 A1 EA201590202 A1 EA 201590202A1 EA 201590202 A EA201590202 A EA 201590202A EA 201590202 A EA201590202 A EA 201590202A EA 201590202 A1 EA201590202 A1 EA 201590202A1
Authority
EA
Eurasian Patent Office
Prior art keywords
buprenorphine
methods
preparations
opioid preparations
depot
Prior art date
Application number
EA201590202A
Other languages
English (en)
Other versions
EA034855B1 (ru
Inventor
Фредрик Тиберг
Иан Харвигссон
Маркус Йонссон
Original Assignee
Камурус Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201590202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Application filed by Камурус Аб filed Critical Камурус Аб
Priority claimed from PCT/EP2013/065855 external-priority patent/WO2014016428A1/en
Publication of EA201590202A1 publication Critical patent/EA201590202A1/ru
Publication of EA034855B1 publication Critical patent/EA034855B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)

Abstract

Предшественник депо-препарата, содержащий: а) матрицу с контролируемым высвобождением; б) по меньшей мере, кислородсодержащий органический растворитель; в) по меньшей мере 12 мас.% по меньшей мере одного активного вещества, выбранного из бупренорфина и его солей, в пересчёте на свободное основание бупренорфина. Предложены соответствующие композиции депо-препаратов и способы лечения, применяемые при купировании боли посредством поддерживающего лечения опиоидами, и родственные способы.
EA201590202A 2012-07-26 2013-07-26 Предшественник депо-препарата, содержащий бупренорфин, и способ лечения путем его введения EA034855B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28
PCT/EP2013/065855 WO2014016428A1 (en) 2012-07-26 2013-07-26 Opioid formulations

Publications (2)

Publication Number Publication Date
EA201590202A1 true EA201590202A1 (ru) 2015-07-30
EA034855B1 EA034855B1 (ru) 2020-03-30

Family

ID=53487482

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590202A EA034855B1 (ru) 2012-07-26 2013-07-26 Предшественник депо-препарата, содержащий бупренорфин, и способ лечения путем его введения

Country Status (20)

Country Link
US (1) US20240075024A1 (ru)
JP (1) JP6417327B2 (ru)
CN (1) CN109010255B (ru)
AU (3) AU2016244271B2 (ru)
CL (1) CL2015000197A1 (ru)
CY (1) CY1124016T1 (ru)
DK (1) DK2877155T3 (ru)
EA (1) EA034855B1 (ru)
ES (1) ES2837803T3 (ru)
HK (2) HK1205948A1 (ru)
HR (1) HRP20210068T1 (ru)
HU (1) HUE053273T2 (ru)
IL (3) IL296882A (ru)
LT (1) LT2877155T (ru)
MX (1) MX361873B (ru)
MY (1) MY189481A (ru)
NZ (2) NZ704012A (ru)
PE (1) PE20150672A1 (ru)
PT (1) PT2877155T (ru)
SG (2) SG10201703964TA (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
WO2019071245A1 (en) * 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
CN117999079A (zh) * 2021-08-20 2024-05-07 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
DK1845942T3 (da) * 2005-01-14 2014-04-28 Camurus Ab GNRH-analogformuleringer
CA2594710C (en) * 2005-01-14 2011-01-25 Camurus Ab Topical bioadhesive formulations
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
IL289157A (en) 2022-02-01
PT2877155T (pt) 2020-12-18
SG11201500554XA (en) 2015-02-27
US20240075024A1 (en) 2024-03-07
MY189481A (en) 2022-02-16
ES2837803T3 (es) 2021-07-01
DK2877155T3 (da) 2021-01-18
IL236762A0 (en) 2015-03-31
JP2015522649A (ja) 2015-08-06
AU2016244271A1 (en) 2016-10-27
AU2019200982B2 (en) 2019-07-18
CY1124016T1 (el) 2022-05-27
AU2017279657B2 (en) 2018-11-15
CL2015000197A1 (es) 2015-11-13
LT2877155T (lt) 2021-02-25
HK1205948A1 (en) 2015-12-31
EA034855B1 (ru) 2020-03-30
AU2019200982A1 (en) 2019-02-28
MX2015001033A (es) 2015-04-09
JP6417327B2 (ja) 2018-11-07
AU2017279657A1 (en) 2018-01-18
CN109010255B (zh) 2022-10-21
MX361873B (es) 2018-12-18
NZ704012A (en) 2017-09-29
PE20150672A1 (es) 2015-05-21
IL296882A (en) 2022-12-01
HRP20210068T1 (hr) 2021-03-05
HK1221636A1 (zh) 2017-06-09
CN109010255A (zh) 2018-12-18
HUE053273T2 (hu) 2021-06-28
NZ735248A (en) 2018-10-26
SG10201703964TA (en) 2017-06-29
AU2016244271B2 (en) 2018-01-18
BR112015001548A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CO7190238A2 (es) Formulaciones de opioides
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
DOP2016000253A (es) Nuevos compuestos
CA3011073A1 (en) Transdermal patch
MX2016013894A (es) Composicion para el cuidado del cuero cabelludo.
MX2017006709A (es) Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales.
EA201790721A1 (ru) Инъекционный состав бупренорфина
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
EA201590202A1 (ru) Опиоидные препараты
UY35338A (es) Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
MX2012013478A (es) Composicion para evitar perdida del cabello o estimular crecimiento del cabello.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
TN2015000037A1 (en) Transdermal formulation containing cox inhibitors
EA201691741A1 (ru) Фармацевтическая композиция
WO2013155483A8 (en) Phototherapy devices and methods comprising optionally substituted quinquiesphenyl compounds
CL2015002188A1 (es) Agentes analgésicos oculares tópicos
AR100444A1 (es) Uso de palmitoiletanolamida en combinación de opioides
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
IN2014KN02584A (ru)
WO2012138190A3 (ko) 병아리꽃나무 추출물을 포함하는 조성물